- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr James Auran Discusses the Transition of Ophthalmic Care to an Outpatient Specialty
James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma, outlines the benefits and challenges of transferring ophthalmic care to outpatient facilities.
Transitioning to an outpatient model provides opportunities for savings and efficiency, said James Auran, MD, a professor of ophthalmology at Columbia University Irving Medical Center and president of the American Society of Ophthalmic Trauma.
Transcript
As ophthalmology has evolved into an outpatient specialty over the past few decades, what challenges have come along with this transition?
I wouldn't look at it so much as challenges, as much as the incredible opportunities for cost savings, for efficiency, and for just making it a more patient-friendly environment. I think it's been a tremendous advance. I've seen very few downsides, although there is one small one with trauma which we could go into. Ophthalmologists, in general, have shied away from caring for trauma. It's disruptive to your practice to have a patient come in who needs immediate care, especially if it's complex. The skill set involved is specialized, and it's not something you want to do once every 2 years. When doctors were hospital-based, it was a little bit more, it'd be more common in their practice to encounter this. The trend toward being in private office groups and in surgery centers has sort of put a lot of eye doctors out of touch with trauma care.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer
June 2nd 2025Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.
Read More
Multicancer Detection Assays Remain Largely Elusive for Early-Stage Disease Detection
June 1st 2025Multicancer early detection tests are revolutionizing cancer screening by using liquid biopsies to screen for multiple cancers from a single blood sample, enhancing patient outcomes by identifying cancers earlier.
Read More
